Cancer: Update on bone-modifying agents in metastatic breast cancer

Nature Reviews Endocrinology

Volumn 7, Issue 7, 2011, Pages 380-381

  Suva, Larry J ^a   Brander, Brooke E ^a   Makhoul, Issam ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DASATINIB; DENOSUMAB; DICKKOPF 1 PROTEIN ANTIBODY; GLEMBATUMUMAB; INTERLEUKIN 8 ANTIBODY; ODANACATIB; PAMIDRONIC ACID; PLERIXAFOR; PROTEIN ANTIBODY; UNCLASSIFIED DRUG; ZOLEDRONIC ACID; BONE DENSITY CONSERVATION AGENT;

BONE METASTASIS; BREAST CANCER; DRUG MECHANISM; DRUG RESEARCH; DRUG TARGETING; HUMAN; MEDICAL SOCIETY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; BONE TUMOR; BREAST TUMOR; CLINICAL TRIAL (TOPIC); FEMALE; FRACTURE; METASTASIS; NOTE; STANDARD;

BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; FEMALE; FRACTURES, BONE; HUMANS; PRACTICE GUIDELINES AS TOPIC; SOCIETIES, MEDICAL;

EID: 79959612749     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2011.80     Document Type: Review

References (10)

1. Suva, L. J., Washam, C., Nicholas, R. W. & Griffin, R. J. Bone metastasis: mechanisms and therapeutic opportunities. Nat. Rev. Endocrinol. 7, 208-218 (2011).
2. Hortobagyi, G. N., et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N. Engl. J. Med. 335, 1785-1791 (1996). (Pubitemid 26412396)
3. Lipton, A., Cook, R. J., Major, P., Smith, M. R. & Coleman, R. E. Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity. Oncologist 12, 1035-1043 (2007). (Pubitemid 350007015)
4. Hillner, B. E., et al. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel. J. Clin. Oncol. 18, 1378-1391 (2000). (Pubitemid 30159858)
5. Hillner, B. E., et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J. Clin. Oncol. 21, 4042-4057 (2003). (Pubitemid 46606220)
6. Van Poznak, C. H., et al. American society of clinical oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J. Clin. Oncol. 29, 1221-1227 (2011).
7. Stopeck, A. T., et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J. Clin. Oncol. 28, 5132-5139 (2010).
8. Cummings, S. R., et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N. Engl. J. Med. 361, 756-765 (2009).
9. Shane, E., et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J. Bone Miner. Res. 25, 2267-2294 (2010).
10. Body, J. J., et al. Effects of denosumab in patients with bone metastases with and without previous bisphosphonate exposure. J. Bone Miner. Res. 25, 440-446 (2010).